<DOC>
	<DOCNO>NCT02817776</DOCNO>
	<brief_summary>This prospective , multicenter , non-randomized clinical evaluation utilize THERMOCOOL SMARTTOUCH® SF catheter compare predetermined performance goal .</brief_summary>
	<brief_title>Review Safety Effectiveness THERMOCOOL SMARTTOUCH® SF Catheter Evaluated Treating Symptomatic PersistenT AF ( PRECEPT )</brief_title>
	<detailed_description>The purpose study demonstrate safety effectiveness THERMOCOOL SMARTTOUCH® SF catheter treatment drug refractory symptomatic persistent atrial fibrillation ( PsAF ) follow standard electrophysiology map RF ablation procedure .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Candidates study must meet ALL follow criterion : 1 . Documented symptomatic persistent AF , define continuous AF sustain beyond 7 day less 1 year document following : . 1 . Physician 's note indicate continuous AF ≥ 7 day 1 year ; AND 2 . Two electrocardiogram ( form rhythm monitor ) show continuous AF , electrocardiogram take least 7 day apart OR 3 . 24hour Holter within 90 day ablation procedure show continuous AF 2 . Failed least one antiarrhythmic drug ( AAD ) ( class I III ) evidence recurrent symptomatic AF , intolerable AAD . 3 . Age 18 year old . 4 . Signed Patient Informed Consent Form ( ICF ) . 5 . Able willing comply pre , post , followup testing requirement . Candidates study EXCLUDED study ANY follow condition apply : 1 . Continuous AF &gt; 12 month ( 1Year ) ( Longstanding Persistent AF ) 2 . Previous surgical catheter ablation atrial fibrillation 3 . Any cardiac surgery within past 2 month ( 60 day ) ( include PCI ) 4 . CABG surgery within past 6 month ( 180 day ) 5 . Valvular cardiac surgical/percutaneous procedure ( i.e. , ventriculotomy , atriotomy , valve repair replacement presence prosthetic valve ) 6 . Any carotid stenting endarterectomy 7 . Documented LA thrombus image 8 . LA size &gt; 50 mm ( parasternal long axis view ) 9 . LVEF &lt; 40 % 10 . Contraindication anticoagulation ( heparin warfarin ) 11 . History blood clot bleed abnormality 12 . MI within past 2 month ( 60 day ) 13 . Documented thromboembolic event ( include TIA ) within past 12 month ( 365 day ) 14 . Rheumatic Heart Disease 15 . Uncontrolled heart failure NYHA function class III IV 16 . Severe mitral regurgitation ( Regurgitant volume ≥ 60 mL/beat , Regurgitant fraction ≥ 50 % , and/or Effective regurgitant orifice area ≥ 0.40cm2 ) 17 . Awaiting cardiac transplantation cardiac surgery within next 12 month ( 365 day ) 18 . Unstable angina 19 . Acute illness active systemic infection sepsis 20 . AF secondary electrolyte imbalance , thyroid disease , reversible noncardiac cause . 21 . Diagnosed atrial myxoma . 22 . Presence implant ICD/CRTD . 23 . Significant pulmonary disease , ( e.g. , restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . 24 . Gastroesophageal Reflux Disease ( GERD ) 25 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study . 26 . Women pregnant ( evidenced pregnancy test premenopausal ) 27 . Enrollment investigational study evaluate another device , biologic , drug . 28 . Presence intramural thrombus , tumor abnormality precludes vascular access , manipulation catheter . 29 . Presence condition precludes appropriate vascular access . 30 . Life expectancy le 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Interventional</keyword>
	<keyword>Radiofrequency Ablation</keyword>
	<keyword>Persistent Atrial Fibrillation</keyword>
</DOC>